Kaya Holdings (KAYS) Net Income towards Common Stockholders (2011 - 2025)

Kaya Holdings (KAYS) recorded quarterly Net Income towards Common Stockholders of -$8.6 million in Q3 2025, down 242.92% quarter-over-quarter from -$2.5 million in Q2 2025, and down 244.3% on a YoY basis from $6.0 million in Q3 2024.

Kaya Holdings (KAYS) Net Income towards Common Stockholders (2011 - 2025) Analysis & Trends

Kaya Holdings' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at -$8.6 million for Q3 2025.

  • In Q3 2025, Net Income towards Common Stockholders fell 244.3% year-over-year to -$8.6 million; the TTM figure through Sep 2025 stood at -$13.9 million (down 336.32% YoY), while the FY2024 annual figure was -$2.2 million, down 235.81% from the prior year.
  • Net Income towards Common Stockholders was -$8.6 million for Q3 2025 at Kaya Holdings, down from -$2.5 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $9.2 million in Q2 2021 to a low of -$13.1 million in Q4 2021.
  • Historically, Net Income towards Common Stockholders has averaged -$1.1 million across 5 years, with a median of -$1.1 million in 2022.
  • The sharpest annual moves came in 2021 and 2024: Net Income towards Common Stockholders jumped 744.03% in 2021, then slumped 1958.97% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$13.1 million in 2021, then jumped by 31.74% to -$9.0 million in 2022, then surged by 100.67% to $60080.0 in 2023, then plunged by 1958.97% to -$1.1 million in 2024, then sank by 669.24% to -$8.6 million in 2025.
  • The last three Net Income towards Common Stockholders figures came in at -$8.6 million (Q3 2025), -$2.5 million (Q2 2025), and -$1.7 million (Q1 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Teva Pharmaceutical Industries 38.77 Bn 35.04 Bn 1.97 Bn 366.00 Mn
2 Zoetis 34.11 Bn 32.16 Bn 1.62 Bn 601.00 Mn
3 United Therapeutics 23.68 Bn 21.53 Bn 648.10 Mn 274.90 Mn
4 Aurora Cannabis 16.48 Bn 16.40 Bn 33.43 Mn 1.99 Mn
5 Neurocrine Biosciences 16.19 Bn 14.88 Bn 800.70 Mn 197.90 Mn
6 Elanco Animal Health 11.44 Bn 11.01 Bn 785.00 Mn 57.00 Mn
7 Alkermes 7.28 Bn 6.77 Bn -116.06 Mn -66.53 Mn
8 Lantheus Holdings 6.48 Bn 5.98 Bn 230.92 Mn 118.42 Mn
9 Hims & Hers Health 6.35 Bn 5.60 Bn 396.79 Mn -92.12 Mn
10 Kaya Holdings - - 5,370.00 -8.59 Mn

Historic Data

Download Data
DateValue
Sep 30, 2025 -8.59 Mn
Jun 30, 2025 -2.51 Mn
Mar 31, 2025 -1.68 Mn
Dec 31, 2024 -1.12 Mn
Sep 30, 2024 -2.50 Mn
Jun 30, 2024 357,210.00
Mar 31, 2024 -1.11 Mn
Dec 31, 2023 60,080.00
Sep 30, 2023 702,407.00
Jun 30, 2023 598,450.00
Mar 31, 2023 67,159.00
Dec 31, 2022 -8.96 Mn
Sep 30, 2022 7.41 Mn
Jun 30, 2022 3.07 Mn
Mar 31, 2022 -1.10 Mn
Dec 31, 2021 -13.13 Mn
Sep 30, 2021 3.95 Mn
Jun 30, 2021 9.18 Mn
Mar 31, 2021 -5.52 Mn
Dec 31, 2020 3.38 Mn